FUELL prototypes displayed in NYC
Italian entrepreneurs plug into Stony Brook; take on Tesla's Powerwall
ENB Therapeutics Announces Clinical Trial Collaboration with Merck
Bioharmony Therapeutics and Boehringer Ingelheim Announce Collaboration for MDR Infections
Accelerate NY Seed fund invested $100,000 in cancer drug developer TargaGenix Inc. The company is commercializing a novel chemotherapy agent developed at Stony Brook University.
Click Here to to Read More